Comparing outcomes of mutation status KRAS biomarker in mCRC
Research type
Research Study
Full title
A local study comparing the outcomes of the mutation status of the biomarker KRAS in patients with metastatic bowel cancer treated with chemotherapy
IRAS ID
149847
Contact name
Megan Llewelyn
Contact email
Sponsor organisation
Mid-Essex NHS Trust
Duration of Study in the UK
0 years, 1 months, 1 days
Research summary
The outcomes for patients with metastatic bowel cancer, identified to have KRAS wild-type positive (This is a tumour marker) disease, are more expected to have improved survival outcomes and disease response to chemotherapy compared to KRAS mutant type.
This retrospective observational study will test this hypothesis by observing outcomes of KRAS wild-type (Tumour Marker) compared to KRAS mutant bowel cancer in patients with metastatic disease treated with a standardised regime of chemotherapy in our local area.
The study population will include all patients identified with metastatic bowel cancer and treated with chemotherapy between December 2010 and January 2012 at Broomfield Hospital, Essex.
The outcomes from both groups in regards to disease response (tumour size) will be recorded up to a year post treatment and conclusions drawn. Data will be collected from the hospital pathology database, Chemotherapy Unit database, imaging, and outpatient letter database using patient hospital numbers.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
15/YH/0083
Date of REC Opinion
1 Apr 2015
REC opinion
Further Information Favourable Opinion